Psychometric evaluation of a visual analog scale for the assessment of anxiety

Health and Quality of Life Outcomes

Volumn 8, Issue , 2010, Pages

  Williams, Valerie S L ^a   Morlock, Robert J ^b   Feltner, Douglas ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b i3 Innovus   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; PAROXETINE;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTRUCT VALIDITY; FEMALE; GENERALIZED ANXIETY DISORDER; GLOBAL ANXIETY VISUAL ANALOG SCALE; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; MENTAL HEALTH; PSYCHOMETRY; SHORT FORM 36; SOCIAL STATUS; TEST RETEST RELIABILITY; VISUAL ANALOG SCALE; ANXIETY DISORDER; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TIME; VALIDATION STUDY;

ADULT; ANXIETY DISORDERS; FEMALE; HUMANS; LORAZEPAM; MALE; MIDDLE AGED; PAROXETINE; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 77953125678     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-8-57     Document Type: Article

References (42)

1. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. Palliat Care 1991, 7:6-9.
2. Kremer E, Atkinson JH, Ignelzi RJ. Measurement of pain: patient preference does not confound pain measurement. Pain 1981, 10:241-248. 10.1016/0304-3959(81)90199-8, 7267140.
3. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976, 2(2):175-184. 10.1016/0304-3959(76)90113-5, 1026900.
4. deBoer AGEM, van Lanschot JJB, Stalmeier PFM, van Sandick JW, Hulscher JBF, de Haes JCJM, Sprangers MAG. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life?. Qual Life Res 2004, 13:311-320. 10.1023/B:QURE.0000018499.64574.1f, 15085903.
5. Hyland ME, Sodergren SC. Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Qual Life Res 1996, 5:469-480. 10.1007/BF00540019, 8973126.
6. Lingjaerde O, Foreland AR. Direct assessment of improvement in winter depression with a visual analogue scale: high reliability and validity. Psychiatry Res 1998, 81:387-392. 10.1016/S0165-1781(98)00119-X, 9925190.
7. Mortimore C, Anderson IM. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacology 2000, 149:251-258. 10.1007/s002139900342, 10823406.
8. Steiner M, Streiner DL. Validation of a revised visual analogue scale for premenstrual mood symptoms: results from prospective and retrospective trials. Can J Psychiatry 2005, 50(6):327-332.
9. Revill SI, Robinson JO, Rosen M, Hogg MI. The reliability of linear analogue scales for evaluating pain. Anaesthesia 1976, 31(9):1191-1198. 10.1111/j.1365-2044.1976.tb11971.x, 1015603.
10. Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health 1990, 13(4):227-236. 10.1002/nur.4770130405, 2197679.
11. Dixon JS, Bird HA. Reproducibility along a 10 cm vertical visual analogue scale. Ann Rheum Dis 1981, 40(1):87-89. 10.1136/ard.40.1.87, 1000664, 7469530.
12. Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Diseases 1987, 40(12):1129-1133.
13. Hamilton M. The assessment of anxiety states by rating. British J Medical Psychology 1959, 32:50-55.
14. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PR, Bielski RJ, Zimbroff DL, Davidson JRT, Liu-Dumaw M. Pregablalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003, 160:533-540. 10.1176/appi.ajp.160.3.533, 12611835.
15. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002, 63(Suppl 14):9-16.
16. Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin WA. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res 2000, 94:179-184. 10.1016/S0165-1781(00)00135-9, 10808043.
17. Graham SJ, Scaife JC, Langley RW, Bradshaw CM, Szabadi E, Xi L, Crumley T, Calder N, Gottesdiener K, Wagner J. Effects of lorazepam on fear-potentiated startle responses in man. J Psychopharmacol 2005, 19(3):249-258. 10.1177/0269881105051528, 15888510.
18. Wolf DL, Desjardins PJ, Black PM, Francom SR, Mohanlal RW, Fleishaker JC. Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: evaluation of alprazolam. J Clin Psychopharmacol 2003, 23(1):51-57. 10.1097/00004714-200302000-00009, 12544376.
19. Covi L, Lipman R, McNair DM, Czerlinsky T. Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol Biol Psychiatry 1979, 3:521-533.
20. Raskin A, Schulterbrandt JG, Reatig N, McKeon JJ. Differential response to chlorpromazine, imipramine and placebo. A study of subgroups of depressed patients. Arch Gen Psychiatry 1970, 23:164-173.
21. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995, 56(6):229-237.
22. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 1982, 18(4):69-77.
23. Snaith RP, Zigmond AS. The Hospital Anxiety and Depression Scale Manual. 1994, Windsor, England: Nfer-Nelson.
24. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
25. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
26. Ware JE, Snow KK, Kosinski M. SF-36 Health Survey: Manual and interpretation guide. 2000, Lincoln RI: QualityMetric Incorporated.
27. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993, 29:321-326.
28. Guy W. ECDEU assessment manual for psychopharmacology (US Department of Health, Education, and Welfare Publication No. 76-338). 1976, Rockville MD: National Institute of Mental Health.
29. Schuck P. Assessing reproducibility for interval data in health-related quality of life questionnaires: which coefficient should be used?. Qual Life Res 2004, 13:571-586. 10.1023/B:QURE.0000021318.92272.2a, 15130022.
30. Shrout PE, Fleiss J. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979, 86:420-428. 10.1037/0033-2909.86.2.420, 18839484.
31. Guyatt GH, Walter SD, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Diseases 1987, 40:171-178.
32. Cohen J. Statistical power analysis for the behavioral sciences. 1988, Hillsdale NJ: Lawrence Erlbaum.
33. Messick S. Validity. Educational measurement 1989. New York: American Council on Education, Macmillan Publishing Co, 3.
34. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Controlled Clin Trials 1989, 10:407-415. 10.1016/0197-2456(89)90005-6, 2691207.
35. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52:861-873. 10.1016/S0895-4356(99)00071-2, 10529027.
36. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003, 56:395-407. 10.1016/S0895-4356(03)00044-1, 12812812.
37. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality-of-life: the remarkable universality of half a standard deviation. Med Care 2003, 41:582-592. 10.1097/00005650-200305000-00004, 12719681.
38. Scrimshaw SV, Maher C. Responsiveness of visual analogue and McGill pain scale measures. J Manipulative Physiol Ther 2001, 24:501-504. 10.1067/mmt.2001.118208, 11677548.
39. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000, 88:2164-2171. 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5, 10813730.
40. Love A, Leboeuf C, Crisp TC. Chiropractic chronic low back pain sufferers and self-report assessment methods: I. A reliability study of the visual analogue scale, the pain drawing, and the McGill Pain Questionnaire. J Manipulative Physiol Ther 1989, 12:21-25.
41. US Department of Health and Human Services, Food and Drug Administration Guidance for industry: Patient-reported outcome measures--Use in medical product development to support labeling claims. Draft guidance released for comment on February 3, 2006 2006, Washington, DC: US Department of Health and Human Services, US Department of Health and Human Services, Food and Drug Administration.
42. Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation - Quality of Life questionnaire in prucalopride (RESOLOR®) trials for chronic constipation. Neurogastroenterol Motil 2009,